The U.S. House of Representatives has passed the HALT Fentanyl Act, designated as S. 331, which is now on its way to President Trump for approval. This legislation is a counterpart to the previously passed H.R. 27, introduced by Representatives Morgan Griffith and Bob Latta.
Congressman Morgan Griffith expressed his views following the passage of the bill: “American communities continue to feel the impact of the fentanyl crisis, fueled in part by lethal fentanyl-related substances. Congressional action passing the HALT Fentanyl Act is a great step to help combat the crisis and save lives. We now deliver this critical bill to President Trump to aid the Administration in their push to fight the fentanyl crisis.”
Earlier this year, on February 6, H.R. 27 was approved by the House. The Senate version, S. 331, received approval on March 14.
The HALT Fentanyl Act aims to permanently classify lethal fentanyl-related substances as Schedule I substances, addressing a loophole that traffickers have been exploiting. Currently, these substances are temporarily classified under Schedule I until September 2025.
Additionally, the bill proposes a streamlined registration process for conducting medical research into fentanyl-related substances.
